Welcome to our dedicated page for Organigram Global news (Ticker: OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Global stock.
News about Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) focuses on its activities as a Canadian cannabis cultivator, manufacturer and brand owner operating under the Cannabis Act and Cannabis Regulations. Company announcements highlight its position as Canada’s number one cannabis company by market share in the recreational segment, as well as developments across cultivation, product innovation, beverages and international expansion.
Investors and observers following OGI news will see regular updates on quarterly and annual financial results, including net revenue trends, adjusted gross margin, adjusted EBITDA and free cash flow, as reported in its earnings releases. These updates often discuss the impact of acquisitions such as Motif Labs Ltd. and Collective Project Limited on revenue growth, extraction capabilities and beverage market participation, along with commentary on cost efficiencies and synergy realization.
Organigram’s news flow also covers product and brand launches. Examples include new SHRED gummies formats, Big Bag O’ Buds strains, BOXHOT infused pre-rolls, Trailblazer blunts, Rizzlers vapes and the happly hemp-derived THC brand in the United States. The company highlights its use of FAST™ nanoemulsion technology in ingestible products and describes how these offerings are designed around consumer preferences, including mood-based formulations.
Another important theme in Organigram news is international and policy-related activity. Releases describe record international sales, progress toward EU-GMP certification for the Moncton facility, exclusive genetics agreements with Phylos Bioscience Inc., and polling and economic reports that position legal cannabis as a contributor to Canada’s GDP, jobs and innovation. Corporate governance and leadership updates, such as CEO succession plans and executive appointments, are also communicated through news releases. For a fuller picture of OGI’s evolving strategy and operations, readers can review this ongoing stream of company disclosures.
Organigram (TSX: OGI, NASDAQ: OGI) announced the appointment of James Yamanaka as Chief Executive Officer, expected to assume the role on or about January 15, 2026 and to join the board at that time. Mr. Yamanaka joins from British American Tobacco after more than 20 years in strategy and general management across Europe and Asia.
Effective December 1, 2025, Board chairman Peter Amirault will serve as interim executive chair to oversee day-to-day management, with Geoff Machum as independent lead director during the transition. The appointment is subject to customary immigration and required procedures.
Organigram (NASDAQ: OGI) released Abacus Data polling (June 25–July 2, 2025, n=2,000) showing 59% of Canadians want the federal government to do more to support jobs and innovation in the legal cannabis sector and 59% view the industry as an important part of the economy. The poll found 35% used cannabis in the past six months.
The release cites Organigram’s 2024 economic estimate: $16B direct GDP, $29B economic output, and 227,000 jobs. The company described priorities: illicit-market enforcement, lower excise taxes, and support for beverages, edibles, and wellness products.
Organigram Global (NASDAQ:OGI, TSX:OGI) said CEO Beena Goldenberg will extend her tenure through November 30, 2025 to support completion of the company's CEO search. The Board reported strong interest in candidates and ongoing progress while Goldenberg continues day-to-day operations to maintain execution and momentum across business lines.
The company highlighted its recent acquisition of Collective Project Limited to participate in US and Canadian cannabinoid beverages markets and summarized its licensed cultivation, processing and manufacturing footprint across Moncton, Lac-Supérieur, Winnipeg, Aylmer and London.
Organigram (NASDAQ: OGI) launched happly, a U.S. hemp-derived THC brand debuting Oct 9, 2025, with three low-dose vegan gummies formulated for Socialize, Relax, and Sleep. Each gummy contains 2.5mg THC (sleep also adds 2.5mg CBN and 10mg CBD) and functional ingredients (caffeine, L-theanine, chamomile). Products use Organigram’s first U.S. deployment of patent-pending FAST™ nanoemulsion tech, clinically validated for ~50% faster onset and nearly double peak cannabinoid delivery versus traditional edibles. happly launches direct-to-consumer at www.gethapply.com, shipping to 23 states, with retail expansion planned later in 2025.
Organigram Global (NASDAQ: OGI) has released a landmark report revealing the substantial economic impact of Canada's legal cannabis industry in 2024. The study, conducted with the Canadian Chamber of Commerce's Business Data Lab, shows that the sector contributed $16 billion to national GDP and generated $29 billion in total economic output.
The cannabis industry directly contributed $8.4 billion to GDP, surpassing traditional sectors like forestry, breweries, and wineries. It supported 227,000 jobs, including 168,000 direct positions in cultivation and retail. The sector generated $2.7 billion in farm cash receipts, outperforming greenhouse and field vegetables.
CEO Beena Goldenberg emphasized the industry's alignment with Prime Minister Carney's One Canadian Economy vision, while noting that outdated policy frameworks and tax structures are limiting the sector's growth potential in the projected CAD $140 billion international market by 2026.
Organigram (NASDAQ: OGI) reported record Q3 Fiscal 2025 results with net revenue reaching $70.8 million, up 72% year-over-year. The company achieved $5.7 million in Adjusted EBITDA (+64% YoY) and $5.0 million in Free Cash Flow.
Key highlights include international revenue of $7.4 million (+208% YoY), Motif synergies of $4.2 million to date, and a strong cash position of $85.9 million with negligible debt. The company maintains its #1 market share position in Canada across multiple categories including vapes, pre-rolls, milled flower, and concentrates.
The company expanded its U.S. presence through hemp-derived THC beverages and launched new products in the Canadian market while achieving a record Moncton harvest of 24,210 kilograms with average THC potency exceeding 29%.
Organigram (NASDAQ: OGI) (TSX: OGI), Canada's leading cannabis company by market share, has scheduled its third quarter fiscal 2025 earnings release for August 13, 2025, before market open.
The company will host a conference call at 8:00 am Eastern Time on the same day to discuss the results. Participants must register in advance through the provided link to receive dial-in details. A webcast option is also available, and a replay will be accessible for 90 days on Organigram's investor relations website.
Organigram Global (NASDAQ: OGI), Canada's leading cannabis company by market share, has launched its Collective Project e-commerce platform across 25 U.S. states, marking a significant expansion into the U.S. hemp-derived THC beverage market.
The platform debuts with a diverse portfolio of hemp-derived THC beverages, including Sparkling Juices and Sparkling Lemonades in various pack sizes and THC dosages. A new line of hemp-derived THC sodas called Fetch is planned for launch later this summer. The company has already secured listings with major retail chains like Total Wine & More and Top Ten Liquors.
The U.S. hemp-derived THC beverage market has exceeded $1 billion in retail sales and is projected to reach $4 billion by 2028. This expansion represents a new revenue stream for Organigram, building on its successful track record and #1 market share position in Canada.
Organigram Global (NASDAQ: OGI) (TSX: OGI) announced that CEO Beena Goldenberg will retire at the end of the fiscal year on September 30, 2025. Under her leadership since 2021, Organigram transformed from an $80M revenue company to Canada's #1 cannabis company by market share, achieving over $250M in net revenue. Key accomplishments include doubling cultivation capacity in Moncton, securing leading positions in vapes, hash, and pre-rolls through three strategic acquisitions, and expanding internationally into Germany, UK, and Australia.
The company's Q2 FY2025 results showed a 74% year-over-year increase in net revenue. The recent acquisition of Collective Project in April 2025 marked Organigram's first revenue from the U.S. market. The Board will initiate a comprehensive CEO selection process to ensure continued growth and innovation leadership.